Reversal of neuromuscular blockage in Patients with End Stage Hepatic Failure (listed for Liver Transplantation)
Phase 1
- Conditions
- Patients with liver-failure undergoing surgery and receiving Rocuronium.Sugammadex is approved for recovery of Rocuronium. There are to date no clinical data to Sugammadex in patients with liver failure.
- Registration Number
- EUCTR2009-012763-34-AT
- Lead Sponsor
- Medizinische Universität Wien, Univ. Klinik für Anästhesie, Allg. Intensivmedizin u Schmerztherapie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
•Endstage liver failure and listing for liver transplantations as pointed out by the department of transplantation surgery
•Age >18 years
•Willingness to participate attested in written consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
•Known allergic reaction to Sugammadex
•Pregnancy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method